Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Squire (2009)
TMPRSS2-ERG and PTEN loss in prostate cancerNature Genetics, 41
Raymond Nagle, A. Algotar, C. Cortez, Katherine Smith, Carol Jones, U. Sathyanarayana, Steve Yun, Janice Riley, D. Nagy, R. Dittamore, B. Dalkin, L. Brosh, G. Pestano (2013)
ERG Overexpression and PTEN Status Predict Capsular Penetration in Prostate CarcinomaThe Prostate, 73
R. Bhalla, L. Kunju, S. Tomlins, Kelly Christopherson, C. Cortez, Shannon Carskadon, J. Siddiqui, K. Park, J. Mosquera, G. Pestano, M. Rubin, A. Chinnaiyan, N. Palanisamy (2013)
Novel Dual Color Immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinomaModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 26
G. Murphy, C. Busch, P. Abrahamsson, J. Epstein, J. McNeal, G. Miller, F. Mostofi, R. Nagle, S. Nordling, C. Parkinson (1994)
Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.Scandinavian journal of urology and nephrology. Supplementum, 162
Copyright © American Society for Investigative Pathology Review Effect of Fixatives and Tissue Processing on the Content and Integrity of Nucleic Acids
Raquel Esgueva, S. Perner, C. LaFargue, V. Scheble, C. Stephan, M. Lein, F. Fritzsche, M. Dietel, G. Kristiansen, M. Rubin (2009)
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohortModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 23
H. Nitta, Wenjun Zhang, Brian Kelly, Melanie Miller, L. Pestic-Dragovich, C. Bieniarz, T. Vasicek, T. Marafioti, L. Rimsza, T. Grogan (2010)
Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models.Methods, 52 4
M. Svensson, C. LaFargue, T. Macdonald, D. Pflueger, Naoki Kitabayashi, A. Santa-Cruz, K. Garsha, U. Sathyanarayana, Janice Riley, Chol Yun, D. Nagy, J. Kosmeder, G. Pestano, A. Tewari, F. Demichelis, M. Rubin (2010)
Testing mutual exclusivity of ETS rearranged prostate cancerLaboratory Investigation; a Journal of Technical Methods and Pathology, 91
K. Sircar, M. Yoshimoto, F. Monzon, I. Koumakpayi, R. Katz, Abha Khanna, K. Alvarez, Guan-Jun Chen, A. Darnel, A. Aprikian, F. Saad, T. Bismar, J. Squire (2009)
PTEN genomic deletion is associated with p‐Akt and AR signalling in poorer outcome, hormone refractory prostate cancerThe Journal of Pathology, 218
Bostwick (2004)
. High-Grade prostatic intraepithelial neoplasia.Rev Urol, 6
Srinivasan (2002)
Effect of fixatives and tissue processing on the content and integrity of nucleic acids.Am J Pathol, 161
G. Murphy, C. Busch, P. Abrahamsson, J. Epstein, J. McNeal, G. Miller, F. Mostofi, R. Nagle, S. Nordling, C. Parkinson, I. Sesterhenn (1994)
Histopathology of localized prostate cancer
R. Reiter (1999)
EDITORIAL: PROSTATE CANCER DIAGNOSTICS—OBSTACLES AND OPPORTUNITIESThe Journal of Urology, 162
Joseph Klink, R. Miocinović, C. Galluzzi, E. Klein (2012)
High-Grade Prostatic Intraepithelial NeoplasiaKorean Journal of Urology, 53
J. King, Jin Xu, John Wongvipat, H. Hieronymus, B. Carver, David Leung, B. Taylor, C. Sander, R. Cardiff, S. Couto, W. Gerald, C. Sawyers (2009)
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesisNature Genetics, 41
B. Han, R. Mehra, R. Lonigro, L. Wang, Khalid Suleman, A. Menon, N. Palanisamy, S. Tomlins, A. Chinnaiyan, R. Shah (2009)
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progressionModern Pathology, 22
Isabel Leiva, M. Emmert-Buck, J. Gillespie (2003)
Handling of clinical tissue specimens for molecular profiling studies.Current issues in molecular biology, 5 2
S. Tomlins, D. Rhodes, S. Perner, S. Dhanasekaran, R. Mehra, Xiao-wei Sun, S. Varambally, Xuhong Cao, J. Tchinda, R. Kuefer, Charles Lee, J. Montie, R. Shah, K. Pienta, M. Rubin, A. Chinnaiyan (2005)
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 310
J. Shuster, R. Lance, D. Troyer (2011)
Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissueBMC Clinical Pathology, 11
K. Park, S. Tomlins, K. Mudaliar, Y. Chiu, Raquel Esgueva, R. Mehra, Khalid Suleman, S. Varambally, J. Brenner, T. Macdonald, A. Srivastava, A. Tewari, U. Sathyanarayana, D. Nagy, G. Pestano, L. Kunju, F. Demichelis, A. Chinnaiyan, M. Rubin (2010)
Antibody-based detection of ERG rearrangement-positive prostate cancer.Neoplasia, 12 7
Jindan Yu, Jianjun Yu, Ram-Shankar Mani, Q. Cao, C. Brenner, Xuhong Cao, Xiaoju Wang, Longtao Wu, James Li, Ming Hu, Y. Gong, Hong Cheng, B. Laxman, A. Vellaichamy, Sunita Shankar, Yong Li, S. Dhanasekaran, R. Morey, T. Barrette, R. Lonigro, S. Tomlins, S. Varambally, Zhaohui Qin, A. Chinnaiyan (2010)
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.Cancer cell, 17 5
S. Bastacky, K. Cieply, C. Sherer, R. Dhir, J. Epstein (2004)
Use of interphase fluorescence in situ hybridization in prostate needle biopsy specimens with isolated high-grade prostatic intraepithelial neoplasia as a predictor of prostate adenocarcinoma on follow-up biopsy.Human pathology, 35 3
J. Mosquera, R. Mehra, M. Regan, S. Perner, E. Genega, Gerri Bueti, R. Shah, S. Gaston, S. Tomlins, John Wei, Michael Kearney, L. Johnson, Jeffrey Tang, A. Chinnaiyan, M. Rubin, M. Sanda (2009)
Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United StatesClinical Cancer Research, 15
Guidance on informed consent for in vitro diagnostic device studies using leftover human specimens that are not individually identifiable
T. Kwast, C. Lopes, C. Santonja, C. Pihl, I. Neetens, Pekka Martikainen, S. Lollo, L. Bubendorf, R. Hoedemaeker (2003)
Guidelines for processing and reporting of prostatic needle biopsiesJournal of Clinical Pathology, 56
(2013)
and Drug Administration
B. Carver, J. Tran, A. Gopalan, Zhenbang Chen, S. Shaikh, A. Carracedo, A. Alimonti, C. Nardella, Shohreh Varmeh, P. Scardino, C. Cordon-Cardo, W. Gerald, P. Pandolfi (2009)
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostateNature Genetics, 41
J. Mosquera, S. Perner, E. Genega, M. Sanda, M. Hofer, K. Mertz, P. Paris, J. Simko, T. Bismar, G. Ayala, R. Shah, M. Loda, M. Rubin (2008)
Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical ImplicationsClinical Cancer Research, 14
Wenjun Zhang, A. Hubbard, P. Brunhoeber, Yixin Wang, Lei Tang (2013)
Automated multiplexing quantum dots in situ hybridization assay for simultaneous detection of ERG and PTEN gene status in prostate cancer.The Journal of molecular diagnostics : JMD, 15 6
A. Angelucci, G. Pace, P. Sanità, C. Vicentini, M. Bologna (2011)
Tissue print of prostate biopsy: a novel tool in the diagnostic procedure of prostate cancerDiagnostic Pathology, 6
RESEARCH ARTICLE Determination of Optimum Formalin Fixation Duration for Prostate Needle Biopsies for Immunohistochemistry and Quantum Dot FISH Analysis Ubaradka G. Sathyanarayana, PhD,* Chandler Birch, BSc,* Raymond B. Nagle, MD, PhD,w Scott A. Tomlins, MD, PhD,zy8 Nallasivam Palanisamy, PhD,z8 Wenjun Zhang, PhD,* Antony Hubbard, BSc,* Patrick Brunhoeber, MD,* Yixin Wang, PhD,* and Lei Tang, PhD* cohort of 18 routinely processed prostate biopsy cores, all cores Abstract: Prostate biopsy is the key clinical specimen for disease were stained successfully with the QD ISH assay, and results diagnosis. However, various conditions used during biopsy were 100% concordant to ERG and PTEN IHC. We conclude processing for histologic analysis may affect the performance of that 8 to 72 hours duration of fixation for prostate needle diagnostic tests, such as hematoxylin and eosin (H&E) staining, biopsies in 10% NBF results in optimal QD ISH assay immunohistochemistry (IHC), or in situ hybridization (ISH). performance. One such condition that may affect diagnostic test performance Key Words: prostate cancer, gene expression, formalin fixed is fixation duration in 10% neutral buffered formalin (NBF). paraffin embedded, IHC, quantum dot, tissue diagnostic For example, prostate needle biopsies are often <1 mm in dia- meter and thus overfixed. It is
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: May 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.